{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000090","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.463877+00:00","generated_at":"2026-06-08T05:20:40.444354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio Q3 net loss $67.4M; restructuring charges $46.3M; cash runway beyond 2026","bullets":["Net loss $67.4M ($0.52 per share) vs $56.2M ($0.43) in Q3 2022.","Cash, equivalents, restricted cash and marketable securities $184.5M, down from $260.9M at Dec 31, 2022.","Restructuring and impairment charges of $46.3M in Q3 2023; none in prior year.","R&D expenses dropped to $8.5M from $39.7M reflecting pipeline reprioritization.","Cash runway expected beyond 2026; ITIL-306 Phase 1 data in NSCLC anticipated in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000090","json":"https://secwatch.observer/filing/0001789769-23-000090.json","markdown":"https://secwatch.observer/filing/0001789769-23-000090.md","text":"https://secwatch.observer/filing/0001789769-23-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/0001789769-23-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/til-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:20:40.444354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4d3ff6410be4ed66e4f3afcf13023068758d25b","claim":"Instil Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss $(67,432) (in thousands), EPS Net loss per share, basic and diluted $(0.52).","evidence_excerpt":"On November 13, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/0001789769-23-000090-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss $(67,432) (in thousands)"},{"label":"EPS","value":"Net loss per share, basic and diluted $(0.52)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}